机器人辅助腹腔镜在肾上腺手术的应用研究进展

周利群; 张争; 韩文聪; 陈仕炜

doi:10.13201/j.issn.1001-1420.2023.11.001

机器人辅助腹腔镜在肾上腺手术的应用研究进展

- 北京大学第一医院泌尿外科北京大学泌尿外科研究所泌尿生殖系疾病(男)分子诊治北京市重点实验室国家泌尿男生殖系肿瘤研究中心(北京，100034)

详细信息

作者简介:
周利群，教授，主任医师，博士生导师。北京大学泌尿外科研究所所长，北京大学医学部泌尿外科学系主任，中国医师学会泌尿外科医师分会名誉会长、前任会长，中华医学会泌尿外科学分会常务委员，中华医学会北京泌尿外科学分会副主任委员，中国医师协会毕业后医学教育外科(泌尿外科方向)专业委员会常务副主任委员，中国研究型医院学会泌尿外科学专业委员会副主任委员，中国医师协会住院医师规范化培训专家委员会泌尿外科专委会副主任委员，CUDA微创及机器人学组组长，CUA微创学组副组长，CUA及CUDA UTUC协作组组长等，CUA UTUC指南编写专家组组长。Current Opinion of Urology 中文版主编，《中华泌尿外科杂志》副主编，《中华腔镜泌尿外科杂志》电子版副主编，《现代泌尿外科杂志》副主编，The Journal of Urology杂志国际编委，《临床泌尿外科杂志》编委。长期致力于泌尿外科的临床及科研工作，擅长复杂性泌尿生殖系统肿瘤的治疗及腹腔镜技术在泌尿外科的应用

通讯作者: 张争，E-mail：doczhz@aliyun.com

中图分类号: R736.6

收稿日期: 2023-09-22

刊出日期: 2023-11-06

Progress in the application of robot assisted laparoscopic surgery in adrenal surgery

- Department of Urology, Peking University First Hospital, Institution of Urology, Peking University, Beijing Key Laboratory of Urogenital Diseases[Male] Molecular Diagnosis and Treatment Center, National Urological Cancer Center, Beijing, 100034, China

More Information

Corresponding author: ZHANG Zheng, E-mail: doczhz@aliyun.com

Received Date: 22 September 2023

Publish Date: 06 November 2023

摘要

摘要: 随着达芬奇手术机器人在泌尿外科领域的广泛应用，机器人辅助腹腔镜下肾上腺切除术(robot assisted laparoscopic adrenalectomy，RALA)已成为肾上腺手术的可选方案之一。尽管对于直径较大、血供丰富、肿瘤边界不清等复杂的肾上腺肿瘤，RALA在肿瘤分离、止血、视野暴露等方面显示出明显优势，但学界对不同类型的肾上腺肿瘤在手术适应证选择和治疗效果方面仍存争议。本文就RALA在肾上腺手术的应用进展作一述评。
- 机器人辅助腹腔镜下肾上腺切除术 /
- 肾上腺皮质癌 /
- 嗜铬细胞瘤
Abstract: With the widespread application of the Da Vinci surgical robot in the field of urology, robot assisted laparoscopic adrenalectomy(RALA) has become one of the optional schemes for adrenal surgery. Although RALA shows obvious advantages in tumor separation, hemostasis, and exposure for complex adrenal tumors with large diameters, rich blood supply, and unclear tumor boundaries, there is still debate in the academia about the selection of surgical indications and treatment effects for different types of adrenal tumors. This article reviews the progress of RALA in adrenal surgery.
- robot assisted laparoscopic adrenalectomy /
- adrenocortical carcinoma /
- pheochromocytoma

HTML全文

参考文献(27)

[1]	Gagner M, Lacroix A, Bolté E. Laparoscopic adrenalectomy in Cushing's syndrome and pheochromocytoma[J]. N Engl J Med, 1992, 327(14): 1033. doi: 10.1056/NEJM199210013271417
[2]	Assalia A, Gagner M. Laparoscopic adrenalectomy[J]. Br J Surg, 2004, 91(10): 1259-1274. doi: 10.1002/bjs.4738
[3]	Yip L, Duh QY, Wachtel H, et al. American Association of Endocrine Surgeons Guidelines for Adrenalectomy: Executive Summary[J]. JAMA Surg, 2022, 157(10): 870-877. doi: 10.1001/jamasurg.2022.3544
[4]	Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline[J]. J Clin Endocrinol Metab, 2014, 99(6): 1915-1942. doi: 10.1210/jc.2014-1498
[5]	Horgan S, Vanuno D. Robots in laparoscopic surgery[J]. J Laparoendosc Adv Surg Tech A, 2001, 11(6): 415-419. doi: 10.1089/10926420152761950
[6]	Ludwig AT, Wagner KR, Lowry PS, et al. Robot-assisted posterior retroperitoneoscopic adrenalectomy[J]. J Endourol, 2010, 24(8): 1307-1314. doi: 10.1089/end.2010.0152
[7]	Brandao LF, Autorino R, Laydner H, et al. Robotic versus laparoscopic adrenalectomy: a systematic review and meta-analysis[J]. Eur Urol, 2014, 65(6): 1154-1161. doi: 10.1016/j.eururo.2013.09.021
[8]	Nomine-Criqui C, Germain A, Ayav A, et al. Robot-assisted adrenalectomy: indications and drawbacks[J]. Updates Surg, 2017, 69(2): 127-133. doi: 10.1007/s13304-017-0448-6
[9]	Gan L, Peng L, Li J, et al. Comparison of the effectiveness and safety of robotic-assisted and laparoscopic in adrenalectomy: A systematic review and meta-analysis[J]. Int J Surg, 2022, 105: 106853. doi: 10.1016/j.ijsu.2022.106853
[10]	Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 2016, 101(5): 1889-1916. doi: 10.1210/jc.2015-4061
[11]	Naruse M, Katabami T, Shibata H, et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021[J]. Endocr J, 2022, 69(4): 327-359. doi: 10.1507/endocrj.EJ21-0508
[12]	Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 2015, 100(8): 2807-2831. doi: 10.1210/jc.2015-1818
[13]	Colvin J, Krishnamurthy V, Jin J, et al. A Comparison of Robotic Versus Laparoscopic Adrenalectomy in Patients With Primary Hyperaldosteronism[J]. Surg Laparosc Endosc Percutan Tech, 2017, 27(5): 391-393. doi: 10.1097/SLE.0000000000000455
[14]	Anceschi U, Tuderti G, Fiori C, et al. Minimally Invasive Partial Versus Total Adrenalectomy for the Treatment of Primary Aldosteronism: Results of a Multicenter Series According to the PASO Criteria[J]. Eur Urol Focus, 2021, 7(6): 1418-1423. doi: 10.1016/j.euf.2020.06.023
[15]	Yiannakopoulou E. Robotic assisted adrenalectomy: Surgical techniques, feasibility, indications, oncological outcome and safety[J]. Int J Surg, 2016, 28: 169-172. doi: 10.1016/j.ijsu.2016.02.089
[16]	Li X, Xiao S, Yu Y, et al. Robotic-assisted laparoscopic adrenalectomy(RARLA): What advantages and disadvantages compared to retroperitoneal laparoscopic adrenalectomy(RLA)?[J]. Front Endocrinol(Lausanne), 2023, 14: 1145820. doi: 10.3389/fendo.2023.1145820
[17]	Zini L, Porpiglia F, Fassnacht M. Contemporary management of adrenocortical carcinoma[J]. Eur Urol, 2011, 60(5): 1055-1065. doi: 10.1016/j.eururo.2011.07.062
[18]	Bharwani N, Rockall AG, Sahdev A, et al. Adrenocortical carcinoma: the range of appearances on CT and MRI[J]. AJR Am J Roentgenol, 2011, 196(6): W706-W714. doi: 10.2214/AJR.10.5540
[19]	Zeiger MA, Thompson GB, Duh QY, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations[J]. Endocr Pract, 2009, 15(5): 450-453. doi: 10.4158/EP.15.5.450
[20]	Gaujoux S, Mihai R, joint working group of ESES and ENSAT. European Society of Endocrine Surgeons(ESES)and European Network for the Study of Adrenal Tumours(ENSAT)recommendations for the surgical management of adrenocortical carcinoma[J]. Br J Surg, 2017, 104(4): 358-376. doi: 10.1002/bjs.10414
[21]	Henry JF, Peix JL, Kraimps JL. Positional statement of the European Society of Endocrine Surgeons(ESES)on malignant adrenal tumors[J]. Langenbecks Arch Surg, 2012, 397(2): 145-146. doi: 10.1007/s00423-011-0893-5
[22]	Stefanidis D, Goldfarb M, Kercher KW, et al. SAGES guidelines for minimally invasive treatment of adrenal pathology[J]. Surg Endosc, 2013, 27(11): 3960-3980. doi: 10.1007/s00464-013-3169-z
[23]	Hue JJ, Ahorukomeye P, Bingmer K, et al. A comparison of robotic and laparoscopic minimally invasive adrenalectomy for adrenal malignancies[J]. Surg Endosc, 2022, 36(7): 5374-5381. doi: 10.1007/s00464-021-08827-x
[24]	Delozier OM, Stiles ZE, Deschner BW, et al. Implications of Conversion during Attempted Minimally Invasive Adrenalectomy for Adrenocortical Carcinoma[J]. Ann Surg Oncol, 2021, 28(1): 492-501. doi: 10.1245/s10434-020-08824-9
[25]	Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors[J]. Cancer, 2008, 113(11): 3130-3136. doi: 10.1002/cncr.23886
[26]	Asher KP, Gupta GN, Boris RS, et al. Robot-assisted laparoscopic partial adrenalectomy for pheochromocytoma: the National Cancer Institute technique[J]. Eur Urol, 2011, 60(1): 118-124. doi: 10.1016/j.eururo.2011.03.046
[27]	Fu SQ, Zhuang CS, Yang XR, et al. Comparison of robot-assisted retroperitoneal laparoscopic adrenalectomy versus retroperitoneal laparoscopic adrenalectomy for large pheochromocytoma: a single-centre retrospective study[J]. BMC Surg, 2020, 20(1): 227. doi: 10.1186/s12893-020-00895-5